The Pharmaceutical Applications of CRISPR-Cas9 and Its Development Trends

Authors

  • Yu Sang

DOI:

https://doi.org/10.61173/1zks4f70

Keywords:

CRISPR-Cas9, pharmaceutical applications, chimeric antigen receptor T cell

Abstract

Originally derived from the immune system of bacteria, CRISPR-Cas9 technology has rapidly developed into a revolutionary gene editing tool that is widely used in molecular biology, drug development, and gene therapy. This technology not only provides a new treatment approach for genetic diseases such as sickle cell anemia and Duchenne muscular dystrophy, but also brings breakthrough progress in cancer treatment by enhancing chimeric antigen receptor T cell (CAR-T) therapy. CRISPR-Cas9 has also shown great potential in the drug discovery stage, especially in gene screening, development of disease models, and drug resistance research. However, with the rapid development of CRISPR technology, the scientific community still needs to solve challenges such as potential off-target effects in gene editing, inefficient delivery systems, and long-term safety. In addition, the ethical issues of gene editing have also sparked widespread discussion, especially how to ensure fair access when treating genetic diseases. Despite many challenges, CRISPR-Cas9 technology still shows great application prospects in the future of drug development and gene therapy.

References

[1] Doudna, J. A., Charpentier, E. The new frontier of genome engineering with CRISPR-Cas9. Science, 2014, 346: 1258096.

[2] Frangoul, H., Altshuler, D., Cappellini, M. D., Chen, Y.- S., Domm, J., Eustace, B. K., Foell, J., de la Fuente, J., Grupp, S., Handgretinger, R., Ho, T. W., Kattamis, A., Kernytsky, A., Lekstrom-Himes, J., Li, A. M., Locatelli, F., Mapara, M. Y., de Montalembert, M., Rondelli, D., Sharma, A., Sheth, S., Soni, S., Steinberg, M. H., Wall, D., Yen, A., Corbacioglu, S. CRISPR- Cas9 gene editing for sickle cell disease and β-thalassemia. New England Journal of Medicine, 2021, 384: 252-260.

[3] Demirci, S., Uchida, N., Tisdale, J. F. Gene therapy for sickle cell disease: An update. Cytotherapy, 2018, 20: 899-910.

[4] Esrick, E. B., Lehmann, L. E., Biffi, A., Achebe, M., Brendel, C., Ciuculescu, M. F., Daley, H., MacKinnon, B., Morris, E., Federico, A., Abriss, D., Boardman, K., Khelladi, R., Shaw, K., Negre, H., Negre, O., Nikiforow, S., Ritz, J., Pai, S.-Y., London, W. B., Dansereau, C., Heeney, M. M., Armant, M., Manis, J. P., Williams, D. A. Post-transcriptional genetic silencing of BCL11A to treat sickle cell disease. New England Journal of Medicine, 2021, 384: 205-215.

[5] Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y. J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., Orkin, S. H., Gregory, R. I., Williams, D. A. Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype. J Clin Invest, 2016, 126: 3868-3878.

[6] Ormond, K. E., Mortlock, D. P., Scholes, D. T., Bombard, Y., Brody, L. C., Faucett, W. A., Garrison, N. A., Hercher, L., Isasi, R., Middleton, A., Musunuru, K., Shriner, D., Virani, A., Young, C. E. Human germline genome editing. Am J Hum Genet, 2017, 101: 167-176.

[7] Long, C., Amoasii, L., Mireault, A. A., McAnally, J. R., Li, H., Sanchez-Ortiz, E., Bhattacharyya, S., Shelton, J. M., Bassel-Duby, R., Olson, E. N. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science, 2016, 351: 400-403.

[8] Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., Bassel-Duby, R., Piercy, R. J., Olson, E. N. Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science, 2018, 362: 86- 91.

[9] Ousterout, D. G., Kabadi, A. M., Thakore, P. I., Majoros, W. H., Reddy, T. E., Gersbach, C. A. Multiplex CRISPR/Cas9-based genome editing for correction of dystrophin mutations that cause Duchenne muscular dystrophy. Nature Communications, 2015, 6: 6244.

[10] Nelson, C. E., Wu, Y., Gemberling, M. P., Oliver, M. L., Waller, M. A., Bohning, J. D., Robinson-Hamm, J. N., Bulaklak, K., Castellanos Rivera, R. M., Collier, J. H., Asokan, A., Gersbach, C. A. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine, 2019, 25: 427-432.

[11] Dever, D. P., Scharenberg, S. G., Camarena, J., Kildebeck, E. J., Clark, J. T., Martin, R. M., Bak, R. O., Tang, Y., Dohse, M., Birgmeier, J. A., Jagadeesh, K. A., Bejerano, G., Tsukamoto, A., Gomez-Ospina, N., Uchida, N., Porteus, M. H. CRISPR/Cas9 genome engineering in engraftable human brain-derived neural stem cells. iScience, 2019, 15: 524-535.

[12] Stadtmauer, E. A., Fraietta, J. A., Davis, M. M., Cohen, A. D., Weber, K. L., Lancaster, E., Mangan, P. A., Kulikovskaya, I., Dean&Francis Yu Sang Gupta, M., Chen, F., Tian, L., Gonzalez, V. E., Xu, J., Jung, I. Y., Melenhorst, J. J., Plesa, G., Shea, J., Matlawski, T., Cervini, A., Gaymon, A. L., Desjardins, S., Lamontagne, A., Salas-Mckee, J., Fesnak, A., Siegel, D. L., Levine, B. L., Jadlowsky, J. K., Young, R. M., Chew, A., Hwang, W. T., Hexner, E. O., Carreno, B. M., Nobles, C. L., Bushman, F. D., Parker, K. R., Qi, Y., Satpathy, A. T., Chang, H. Y., Zhao, Y., Lacey, S. F., June, C. H. CRISPR- engineered T cells in patients with refractory cancer. Science, 2020, 367: 73-80.

[13] Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., Marson, A. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Scientific Reports, 2017, 7: 737.

[14] Choi, B. D., Yu, X., Castano, A. P., Darr, H., Henderson, D. B., Bouffard, A. A., Larson, R. C., Scarfò, I., Bailey, S. R., Gerhard, G. M., Frigault, M. J., Leick, M. B., Schmidts, A., Sagert, J. G., Curry, W. T., Carter, B. S., Maus, M. V. CRISPR- Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma. Journal for ImmunoTherapy of Cancer, 2019, 7: 304.

[15] Li, D., Li, X., Zhou, W.-L., Huang, Y., Liang, X., Jiang, L., Yang, X., Sun, J., Li, Z., Han, W.-D., Wang, W. Genetically engineered T cells for cancer immunotherapy. Signal Transduction and Targeted Therapy, 2019, 4: 35.

[16] Liu, X., Zhang, Y., Cheng, C., Cheng, A. W., Zhang, X., Li, N., Xia, C., Wei, X., Liu, X., Wang, H. CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells. Cell Research, 2017, 27: 154-157.

[17] Nobles, C. L., Sherrill-Mix, S., Everett, J. K., Reddy, S., Fraietta, J. A., Porter, D. L., Frey, N., Gill, S. I., Grupp, S. A., Maude, S. L., Siegel, D. L., Levine, B. L., June, C. H., Lacey, S. F., Melenhorst, J. J., Bushman, F. D. CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. J Clin Invest, 2020, 130: 673-685.

[18] Sherkow, J. S., Zettler, P. J., Greely, H. T. Is it ‘gene therapy’? Journal of Law and the Biosciences, 2018, 5: 786-793.

Downloads

Published

2025-06-26

Issue

Vol. 3 No. 3 (2025): Volume 3, Issue 3

Section

Articles

License

Copyright (c) 2025 by the authors.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.